文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

高渗乳酸钠输注减少实验性心脏骤停后血管升压药需求及脑和心肌损伤生物标志物

Hypertonic sodium lactate infusion reduces vasopressor requirements and biomarkers of brain and cardiac injury after experimental cardiac arrest.
PubMed 文献 · Crit Care · 2023-04-22
一句话结论猪心脏骤停模型中,高渗乳酸钠(心肺复苏期间或自主循环恢复后输注)减少维持平均动脉压>65 mmHg所需的血管升压药,并降低心肌肌钙蛋白I和GFAP水平。

该研究在35只成年猪中建立10分钟电诱发心脏骤停+5分钟心肺复苏模型,随机分为平衡晶体液对照组(n=11)、心肺复苏期间开始高渗乳酸钠组(n=12)和自主循环恢复后开始高渗乳酸钠组(n=11),均治疗12小时并实施34℃目标温度管理。34/35(97.1%)动物实现自主循环恢复。高渗乳酸钠组动脉pH、乳酸、钠浓度和血浆渗透压高于对照组(p<0.001),钾浓度较低(p=0.004)。两个高渗乳酸钠组维持平均动脉压>65 mmHg所需的血管升压药均少于对照组(交互作用p=0.005;组间p=0.01),且多个时间点血浆肌钙蛋白I和胶质纤维酸性蛋白(GFAP)浓度低于对照组。

要点

  • 猪心脏骤停模型中,心肺复苏期间或自主循环恢复后输注高渗乳酸钠,均减少维持平均动脉压>65 mmHg所需的血管升压药(交互作用p=0.005;组间p=0.01)。
  • 高渗乳酸钠组多个时间点血浆肌钙蛋白I和胶质纤维酸性蛋白(GFAP)浓度低于对照组。
  • 高渗乳酸钠组动脉pH、乳酸、钠浓度和血浆渗透压高于对照组(p<0.001),钾浓度低于对照组(p=0.004)。
  • 34/35(97.1%)动物实现自主循环恢复;心肺复苏期间开始高渗乳酸钠组有1只动物在完成观察期前死亡。
  • 所有动物均接受34℃目标温度管理,高渗乳酸钠输注持续12小时。

适用人群与场景

  • 成年猪(n=35)电诱发10分钟心脏骤停后接受5分钟心肺复苏的实验模型。

处置流程与药物剂量

  • 高渗乳酸钠组分别于心肺复苏期间(Intra-arrest,n=12)或自主循环恢复后(Post-ROSC,n=11)开始输注,持续12小时;对照组(n=11)接受平衡晶体液。
  • 所有动物均实施34℃目标温度管理。
  • 血管升压药滴定目标为维持平均动脉压>65 mmHg。

研究设计与关键结果

  • 研究类型:实验性心脏骤停猪模型,35只成年猪随机分为平衡晶体液对照组(n=11)、心肺复苏期间高渗乳酸钠组(n=12)和自主循环恢复后高渗乳酸钠组(n=11)。
  • 34/35(97.1%)动物实现自主循环恢复;心肺复苏期间高渗乳酸钠组有1只动物在完成观察期前死亡。
  • 高渗乳酸钠组动脉pH、乳酸、钠浓度和血浆渗透压高于对照组(p<0.001),钾浓度低于对照组(p=0.004)。
  • 与对照组相比,心肺复苏期间和自主循环恢复后高渗乳酸钠输注均改善血流动力学状态,表现为维持平均动脉压>65 mmHg所需的血管升压药减少(交互作用p=0.005;组间p=0.01)。
  • 高渗乳酸钠组多个时间点血浆肌钙蛋白I和胶质纤维酸性蛋白(GFAP)浓度低于对照组。

证据类型、等级与局限

  • 证据类型:实验性动物研究(猪心脏骤停模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在此实验性心脏骤停模型中,高渗乳酸钠输注与血管升压药需求减少及心肌和脑损伤生物标志物血浆浓度降低相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Prognosis after resuscitation from cardiac arrest (CA) remains poor, with high morbidity and mortality as a result of extensive cardiac and brain injury and lack of effective treatments. Hypertonic sodium lactate (HSL) may be beneficial after CA by buffering severe metabolic acidosis, increasing brain perfusion and cardiac performance, reducing cerebral swelling, and serving as an alternative energetic cellular substrate. The aim of this study was to test the effects of HSL infusion on brain and cardiac injury in an experimental model of CA.

METHODS: After a 10-min electrically induced CA followed by 5 min of cardiopulmonary resuscitation maneuvers, adult swine (n = 35) were randomly assigned to receive either balanced crystalloid (controls, n = 11) or HSL infusion started during cardiopulmonary resuscitation (CPR, Intra-arrest, n = 12) or after return of spontaneous circulation (Post-ROSC, n = 11) for the subsequent 12 h. In all animals, extensive multimodal neurological and cardiovascular monitoring was implemented. All animals were treated with targeted temperature management at 34 °C.

RESULTS: Thirty-four of the 35 (97.1%) animals achieved ROSC; one animal in the Intra-arrest group died before completing the observation period. Arterial pH, lactate and sodium concentrations, and plasma osmolarity were higher in HSL-treated animals than in controls (p < 0.001), whereas potassium concentrations were lower (p = 0.004). Intra-arrest and Post-ROSC HSL infusion improved hemodynamic status compared to controls, as shown by reduced vasopressor requirements to maintain a mean arterial pressure target > 65 mmHg (p = 0.005 for interaction; p = 0.01 for groups). Moreover, plasma troponin I and glial fibrillary acid protein (GFAP) concentrations were lower in HSL-treated groups at several time-points than in controls.

CONCLUSIONS: In this experimental CA model, HSL infusion was associated with reduced vasopressor requirements and decreased plasma concentrations of measured biomarkers of cardiac and cerebral injury.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Annoni F, Su F, Peluso L, et al. Hypertonic sodium lactate infusion reduces vasopressor requirements and biomarkers of brain and cardiac injury after experimental cardiac arrest. Crit Care. 2023. PMID: 37087454. doi:10.1186/s13054-023-04454-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。